

A High-content Screening Assay based on Automated Microscopy for Monitoring Antibiotic Susceptibility of Mycobacterium Tuberculosis Phenotypes

Sadaf Kalsum

Linköping University

Blanka Andersson

Linköping University

Jyotirmoy Das

Linköping University

Thomas Schön

Linköping University

Maria Lerm (✉ maria.lerm@liu.se)

Linköping University

Research Article

Keywords: cording, planktonic, Mycobacterium tuberculosis, whole cell screening, automated live-cell imaging

Posted Date: January 7th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-133359/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **A high-content screening assay based on automated microscopy for**
2 **monitoring antibiotic susceptibility of *Mycobacterium tuberculosis***
3 **phenotypes**

4
5 Sadaf Kalsum^{1*}, Blanka Andersson^{1*}, Jyotirmoy Das¹, Thomas Schön² and Maria Lerm¹

6
7
8 ¹Division of Inflammation and Infection, ²Division of Clinical Microbiology

9 Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences,
10 Linköping University, SE-58185, Linköping, Sweden.

11
12 *) Shared first authorship

13 *Corresponding author:*

14 Maria Lerm, Professor in Medical Microbiology

15 Div. of Inflammation and Infection, Lab 1, floor 12

16 Dept. of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences

17 Linköping University

18 SE-58185 Linköping, Sweden

19 Phone: +46-732707786

20 E-mail: maria.lerm@liu.se

21 **Abstract**

22 **Background**

23 Assays enabling efficient high throughput drug screening are necessary for the discovery of
24 new anti-mycobacterial drugs. The purpose of our work was to develop and validate an assay
25 based on live-cell imaging which can monitor growth of two distinct phenotypes of
26 *Mycobacterium tuberculosis* and to test their susceptibility to commonly used TB drugs.

27 **Results**

28 Both planktonic and cording phenotypes were successfully monitored as fluorescent objects
29 using the live-cell imaging system Incucyte S3, allowing collection of data describing distinct
30 characteristics of aggregate size and growth. The quantification of changes in total area of
31 aggregates was used to define IC50 and MIC values of selected TB drugs which revealed that
32 the cording phenotype grew more rapidly and displayed a higher susceptibility to rifampicin. A
33 checkerboard approach, testing pair-wise combinations of sub-inhibitory concentrations of
34 drugs, revealed rifampicin, linezolid and pretomanid as superior in inhibiting growth of cording
35 phenotype.

36 **Conclusion**

37 Our results emphasize the efficiency of using automated live-cell imaging and its potential in
38 high-through put whole-cell screening to evaluate existing and search for novel
39 antimycobacterial drugs.

40 **Keywords**

41 cording, planktonic, *Mycobacterium tuberculosis*, whole cell screening, automated live-cell
42 imaging

43 **Background**

44 Tuberculosis (TB) stands out as one of the most prevalent disease worldwide with a medication
45 period largely extending that of other bacterial infections. The treatment of TB requires 6-9
46 months of chemotherapy with multiple drugs and is hampered by spread of antibiotic resistance,
47 narrowing the therapeutic options. The conventional anti-TB drugs have been in use for many
48 decades and the need to broaden their palette is urgent, pushed by an increase in incidence of
49 multidrug-resistant and extensively drug-resistant TB cases. The search for new treatment
50 regimens has resulted in the identification of several candidates, including new compounds or
51 repurposed drugs (1).

52 Prolonged treatment and variable susceptibility to antibiotics can be attributed to the
53 heterogeneity of populations of *Mycobacterium tuberculosis* (Mtb, the causative agent of TB),
54 which exists in diverse phenotypes both *in vitro* and *in vivo*. The inherent ability of Mtb to form
55 organized aggregates has been known for several decades (2) and has been often related to
56 virulence. Cording mycobacteria grow aligned into tight bundles, where the orientation of the
57 long axis of each bacterial cell within the cord is parallel to the long axis of the cord (3, 4). As
58 we have previously demonstrated, the cording phenotype represents more intrusive interaction
59 with immune cells causing macrophages to release macrophage extracellular traps (METs) (5).
60 Recently, the cording phenotype has been shown to cause extensive immunopathological
61 changes associated with active TB in C3HeB/FeJ mice (6). Mtb cords were also identified
62 inside human alveolar macrophages obtained from patients with active TB (7) and lymphatic
63 endothelial cells isolated from patients with extrapulmonary TB (8).

64 Phenotypic drug screening based on the response of growing bacterial cultures allows the
65 identification of a broader spectrum of inhibitors regardless on mechanism of their action. This
66 so-called “whole-cell screening” has the advantage over target-based screening that only

67 molecules that can penetrate and actually kill/prevent growth of bacteria are selected as hits (9,
68 10). This approach led to the discovery of bedaquilin, one of the few recently introduced drugs
69 (11). More efficient methods based on reporter strains, such as H37Rv carrying bioluminescent
70 or fluorescent genes, has facilitated the discovery of several lead compounds (12). Due to the
71 phenotypic heterogeneity of mycobacteria, the need for combination of several anti-microbial
72 drugs with different modes of action will continue to be a cornerstone in TB treatment. Even if
73 all possible combinations cannot be tested, high throughput assays allowing pairwise
74 combinations can generate essential information for mathematical models to predict high-order
75 interactions (13). Image-based assays bring another dimension into drug screening and if
76 automated imaging systems are used with live cultures, data reflecting the growth kinetics and
77 morphological appearance of the models can be feasibly collected. Their power for drug
78 discovery based on investigating the intracellular fate of Mtb treated with anti-microbial
79 compounds has been demonstrated in multiple studies (14-18) but to our knowledge no imaging
80 assays analysed the growth of axenic mycobacterial cultures.

81 Since there is evidence that cording represents an important intracellular phenotype and
82 considering the potential importance of various phenotypes in compound discovery, we
83 developed and validated an assay based on automated live-cell imaging to monitor growth of
84 two distinct phenotypes of Mtb and used it in a checkerboard approach to analyse the effect of
85 combinations of commonly used as well as recently developed TB drugs.

86

87 **Results**

88 Distribution of aggregates sizes reflects the bacterial phenotype and is altered
89 during bacterial growth


90 In line with our previous findings (5), planktonic bacteria (originating from standing cultures
91 in Middlebrook 7H9 broth with Tween-80) grew as small, dispersed aggregates (Fig. 2A, day-
92 2), while the cording phenotype (obtained from shaken cultures in Middlebrook 7H9 broth
93 without Tween-80) formed more organized structures characteristic for mycobacterial cording
94 (Fig. 2B, day-2). The phenotypic differences persisted throughout the experiment although the
95 growth conditions were identical for both phenotypes (Tween-80-free cell culture medium)
96 from the initiation of the experiment (Fig. 2A-B). In a parallel experiment, bacteria originating
97 from standing cultures were seeded in wells with Middlebrook 7H9 broth with or without
98 Tween-80. Again, the absence of Tween-80 promoted the cording phenotype (Fig. 2C). We
99 reasoned that use of cell culture medium, in our case Dulbeccos's Modified Eagle Medium
100 (DMEM) with human serum instead of conventional broth could be an advantage if our assay
101 would be later optimized for drug screening using infected human cells. The fluorescent
102 bacterial aggregates were then classified by size and their number in each category was
103 summarized in frequency plots. Day 0 in experiments was defined as a time point when
104 antibiotics were added to the bacterial suspension. In the freshly harvested cultures (day -2),
105 the planktonic bacteria contained a significantly higher number of small aggregates between 5-
106 $100 \mu\text{m}^2$ as compared to the cording phenotype (Fig. 2D, Additional file 1: Table S1). On day
107 5 both phenotypes showed an increase in frequency in larger categories due to the growth of
108 bacteria as enlarging aggregates rather than as separated cells. The planktonic phenotype
109 contained significantly more smaller aggregates (between 10 and $500 \mu\text{m}^2$) and similarly to day
110 -2, there were no aggregates larger than $1000 \mu\text{m}^2$, whereas the cording phenotype contained
111 aggregates in all larger categories (Fig. 2E, Additional file 1: Table S1).

112

113

114

115 **Fig. 2. Morphological appearance and size of aggregates in planktonic and cording**
 116 **models.** H37Rv growing in DMEM as planktonic (A) and cording (B) bacteria are shown at
 117 different time points. H37Rv grown in broth with or without Tween-80 (Tween) as indicated
 118 (C). Frequency plots of the distribution of aggregate sizes at day -2 (D) and day 5 (E). Columns
 119 represent size intervals and are logarithmically distributed up to $10^4 \mu\text{m}^2$. NP (non-present)
 120 marks intervals where no objects were identified. Data are presented as mean \pm SD (N=3).



121

122

123 We also investigated possibility to visualize the continuous changes in area of single aggregates.

124 Since the Incucyte software does not allow following changes in area of single objects, images

125 were analyzed through the MATLAB image processing tool to follow up the growth of
126 individual aggregates (Additional file 8: Movie S1).

127 Distribution of aggregate sizes reflects antibiotic exposure

128 In order to investigate whether the distribution of aggregates sizes could be affected by
129 antibiotic treatment, we treated the cultures with different concentrations of rifampicin (RIF).
130 At the lowest concentration (1×10^{-6} $\mu\text{g/ml}$), the frequency of larger aggregates increased
131 significantly with time whereas frequency of smaller aggregates significantly decreased (Fig.
132 3E, F) comparably to the growth of untreated H37Rv (Fig. 3G, H). In contrast, the frequency
133 of aggregates in wells treated by highest concentration of RIF ($10 \mu\text{g/ml}$) remained unchanged
134 with time (Fig. 3A, B). A moderate shift in frequencies was observed in wells treated with an
135 intermediate dose of RIF (1×10^{-3} $\mu\text{g/ml}$, Fig. 3C, D). Similar results were observed for bacteria
136 treated with isoniazid (INH) (Fig. 4 A-H).

137

138

139

140

141


142

143


144

145

146 **Fig. 3. Frequency of aggregate sizes during bacterial growth and in response to rifampicin**
 147 **(RIF).** A, C, E) Frequency plots summarizing data from planktonic phenotype and B, D, F)
 148 data from cording phenotype exposed to different concentrations of rifampicin after 3 and 5
 149 days of incubation. G, H) Frequency plots of untreated controls for planktonic and cording
 150 phenotype respectively. Data are presented as mean \pm SD (N=3).



152 **Fig. 4. Frequency of aggregate sizes during bacterial growth and in response to isoniazid**
 153 **(INH).** A, C, E) Frequency plots summarizing data from planktonic phenotype and B, D, F)
 154 data from cording phenotype exposed to different concentrations of isoniazid after 3 and 5 days
 155 of incubation. G, H) Frequency plots of untreated controls for planktonic and cording phenotype
 156 respectively. Data are presented as mean \pm SD (N=3).



157

158 IC50 and MIC determination show higher susceptibility of cording phenotype to
159 antibiotics

160 Next, to validate the usefulness and accuracy of the method, we set out to determine the
161 Inhibitory Concentration 50 (IC50) and Minimal Inhibitory Concentration (MIC) of RIF and
162 INH and other first- and second-line TB antibiotics (Table 1) for the respective phenotype. As
163 the initial inoculum and growth rate differed between the two phenotypes (Additional file 2:
164 Fig S1), we normalized the growth after antibiotic treatment to the untreated controls for each
165 phenotype separately (Additional files 3-6: Fig. S2-5) after establishing that growth
166 measurements of untreated bacteria performed with reliable reproducibility. Intra-assay
167 variability at day 5 was 6,1%, 16,1% and 8,2% for the planktonic and 10,6%, 13,6% and 17,8%
168 for the cording phenotypes, respectively, in each of three experiments. Inter-assay variability
169 based on data from all three experiments was 10,1% for the planktonic and 19,9% for the
170 cording model (Additional file 7: Table S2).

171 To compare IC50 and MIC between phenotypes, we extracted day 5 data from cultures treated
172 with 13 stepwise diluted concentrations of RIF and INH and plotted both IC50 and MIC values
173 in figures 5 and 6. The results obtained with this analysis of the RIF data revealed the cording
174 phenotype as slightly more susceptible to the treatment than the planktonic, with both IC50 and
175 MIC values (Table 1, Fig. 5A, Fig. 6A-B) being twice as high. Similarly, cording bacteria
176 showed a higher INH-susceptibility over planktonic when comparing IC50 values (Table 1, Fig.
177 5B), while the MIC values of both was very similar (Table 1, Fig. 6C-D). Both IC50 and MIC
178 values for all antibiotics tested followed the same trend with the cording phenotype being more
179 susceptible compared to the planktonic (Table 1). After transposition of MIC values to nearest
180 highest MIC according to ISO standard (Table 1), the difference between planktonic and
181 cording phenotypes faded. Finally, in order to evaluate possible additive and synergistic effects

182 of antibiotics on the studied phenotypes, we performed a checkerboard assay with antibiotics
 183 at sub-inhibitory concentrations (concentrations summarized in Table 2). The experiment
 184 revealed that the cording phenotype was more susceptible to the combination of rifampicin,
 185 linezolid and pretomanid with several other drugs as compared to the planktonic bacteria (Fig.
 186 7).

187 **Table 1. IC50 and MIC values for antibiotics.**

Antibiotic	IC50		MIC/Standard MIC**	
	planktonic	cording	planktonic	cording
Rifampicin	0.0013	0.00070	0.017/0.016	0.0088/0,016
Isoniazid	0.00074	0.00036	0.0021/0,004	0.0028/0,004
Linezolid	0.36	0.15	1.7*/2	1.1*/1
Levofloxacin	0.29	0.23	1.1*/1	0.91*/1
Ethambutol	0.97	0.77	8.0*/8	6.4*/8
Clofazimine	0.28*	0.081*	0.31/0,5	ND
Moxifloxacin	0,019*	0,0037*	ND	ND
Pretomanid	0,073*	0,037*	ND	ND

188 *not enough data to detect one or both limits of confidential interval (95%)

189 **MIC value transposed to nearest higher one according to the ISO standard

190 ND no value detected


191

192

193

194 **Fig. 5. Dose response to antibiotics.** Total area of aggregates in wells treated with antibiotics
 195 normalized to median of untreated controls (N=33) were used to calculate IC50 values. Black
 196 dotted line represents IC50 value for planktonic and red dotted line IC50 value for cording
 197 phenotype as determined by nonlinear regression (inhibitor vs response) with 4 parameters (A,


198 B) or 3 parameters (C-H). Data are presented as mean of three experiments \pm SD. Dotted lines
 199 cross x-axes at the point representing IC50 value for planktonic (black line) and cording (red
 200 line) models.



201

202

203 **Fig. 6. MIC values for rifampicin (RIF) and isoniazid (INH).** Gompertz functions was used
204 to calculate MIC values at day5 based on total area of aggregates normalized to median of
205 untreated controls (N=33) of the A), C) planktonic and B), D) cording model.



206

207

208

209


210

211

212

213

214 **Fig. 7. Inhibition of Rv growth by combination of antibiotics.** H37Rv were treated by
 215 combination of two antibiotics at sub-inhibitory concentrations (details in Table 2). Total area
 216 of aggregates in wells treated with antibiotics normalized to median of untreated controls
 217 (N=33) were used in analysis. Data are presented as mean \pm SD (N=3).



218

219

220 **Discussion**

221 Our major goal in this study was to evaluate possibility to use automated live-cell imaging
222 system Incucyte S3 for high-through put screening of assessment of TB drug susceptibility and
223 compound libraries. We included two distinct phenotypes of Mtb in our high-content screening
224 assay and investigated the potential differences in their antibiotic susceptibility. We could
225 detect differences between the phenotypes as change of frequency in sizes of mycobacterial
226 aggregates and monitor their growth and response to antibiotics. We were also able to calculate
227 IC50 and MIC values for RIF and INH and the other antibiotics tested.

228 Heterogeneity of mycobacterial phenotypes in infected tissues and changing microenvironment
229 during the course of TB poses a challenge for successful treatment that eliminates all forms of
230 the pathogen. As we and others have previously demonstrated, the cording phenotype has
231 possible bearings on TB severity, as it contributes to the pathophysiology (7, 8) and causes
232 MET formation in infected macrophages (5). This prompted us to compare the effect of
233 antibiotics on cording and planktonic mycobacteria.

234 Bacterial suspension is routinely homogenized as prerequisite for assessment of its
235 concentration with help of OD measurements (19, 20). Although the generation of planktonic
236 and cording bacteria occurred in broth, the phenotypes were keeping their distinct character in
237 the cell culture medium we used afterwards. Even if the main niche of Mtb is the intracellular
238 environment, mycobacteria in general often prevail extracellularly as cords (21, 22) and we
239 reasoned that DMEM could better reflect such situations than enriched bacterial growth
240 medium.

241 Detergents as Tween-80 in mycobacterial cultures ensures the dispersion of cells, promoting a
242 homogenous culture, but the presence of detergent causes an artificial condition that can affect
243 the growth characteristics and therefore also antibiotic susceptibility. It has been reported for

244 bedaquiline, that antibiotic susceptibility, measured as MIC, changes with Tween-80
245 concentration (23) since detergent might interact with the antibiotic or even penetrate
246 mycobacterial cell walls as reviewed by Leisching et al (24). Phagocyte internalization of Mtb
247 and the subsequent innate immune response can be affected by the presence of detergent in the
248 culture medium (25). Even if results of assays with planktonic, ideally dispersed, bacterial cells
249 can certainly be more reproducible in phenotypic drug-screening assays (26), they will not
250 inform the development of drugs with optimal *in vivo* efficacy. Even with aggregating bacteria
251 grown without detergent, we found variability of measurements in our experiments (less than
252 20%) acceptable for the purpose of the assay.

253 The recorded data enabled us to reliably determine IC50 and MIC values for RIF and INH.
254 Even though MICs were not determined in a standard method and using slightly different
255 definitions than in clinical practice, they were in the range of clinical isolates in BACTEC 960
256 MGIT for RIF (0.016-0.125 mg/L) but slightly lower for INH (0.03-0.064 mg/L) (27, 28). Even
257 if too few concentrations were used for the other tested antibiotics to determine IC50 and MIC
258 values with sufficient certainty, they all seemed to follow similar trend with lower values for
259 cording phenotype comparing to planktonic. The difference in antibiotic susceptibility between
260 both phenotypes estimated by mathematical approximation disappeared after the MIC values
261 were transposed to their ISO standards indicating that it was a marginal difference and should
262 be interpreted with caution and more experimental evidence including larger range of tested
263 concentrations would be needed to confirm that. It has been shown that cords consist of bacterial
264 cells with smaller volume than cells in non-cording aggregates which can indicate more active
265 replication within the cord (8). In line with this, the total area of cording bacteria was increasing
266 much faster from the initial time point than the planktonic, which we have also shown
267 previously (5).

268 The live-cell imaging system we used enabled automated collection of images in chosen
269 intervals during whole experiment without disturbing the experimental model. High-throughput
270 monitoring of single bacterial aggregates brings the analysis of heterogeneous systems to a new
271 level, similarly to single-cells omics approaches.

272

273 **Conclusion**

274 We validated the live-cell imaging system Incucyte S3 for high-throughput screening of the
275 growth and antibiotic susceptibility of two distinct phenotypes of Mtb. We were able to follow
276 their growth dynamics and measure important parameters of drug activity such as IC50 and
277 MIC values.

278

279 **Methods**

280 **Bacterial culture**


281 H37Rv (American Type Culture Collection, ATCC 27294) harboring the pFPV2- plasmid
282 encoding the green fluorescent protein (GFP) was grown and prepared as previously described
283 (5). In short, the bacteria were grown for 2-3 weeks at 37°C in Middlebrook 7H9 medium (BD
284 Biosciences, USA) supplemented with 0.05% Tween-80 and albumin-dextrose-catalase
285 enrichment (ADC, Becton Dickinson) using 20 µg/ml of kanamycin (Sigma-Aldrich, MO) as a
286 selective antibiotic. The bacteria were reseeded as standing and shaken cultures before the
287 experiment. The standing culture was passaged in a new medium with 0.05% Tween-80 and
288 incubated at 37°C for additional 5 days while the shaken culture was made in medium without
289 Tween-80 and put on a shaker at 260 rpm 3 days prior to the experiment.

290 Experimental protocol

291 The bacterial suspensions from both tubes (i.e. shaken and standing) were prepared as described
292 earlier (29). Briefly, the bacterial suspensions were centrifuged twice at 5,000 x g for 5 min in
293 phosphate-buffered saline (PBS) supplemented with 0.05% Tween-80 and passed through a
294 sterile syringe equipped with 27-gauge needle to remove bacterial aggregates. After the final
295 wash, bacterial pellets from both tubes were resuspended in antibiotic-free DMEM (Gibco)
296 containing 25 mM HEPES (Gibco), 2 mM L-glutamine (Gibco) and 10% active human serum
297 (pooled from 5 healthy donors, blood bank of Linköping University Hospital) (ABF medium)
298 and the concentration as CFU/ml was determined by measuring optical density (OD₆₀₀). Since
299 ABF medium is commonly used in our lab in models of Mtb growing intracellularly in human
300 cells and supports bacterial growth very effectively, we decided to continue cultivation in it
301 after phenotypes have been generated in broth. Finally, 35 µl of each bacterial suspension was
302 seeded in separate 384-well black clear-bottom plates (BD, Falcon) and placed in Incucyte S3
303 (IncuCyte® Live-Cell Analysis System, Sartorius) for live cell imaging at 37°C for 48 hours to
304 allow initiation of growth in the DMEM. Images (2/well) at 20x magnification were captured
305 with 2 h intervals. Selected first and second-line antibiotics available for TB treatment were
306 dissolved either in sterile, deionized water or 100% dimethyl sulfoxide (DMSO) to obtain stock
307 solutions and then diluted in ABF medium to achieve the final required concentrations
308 (summarized in Table 2). 35 µl of 2 times the final concentration of antibiotic solutions was
309 added in respective wells after 48 hours of addition of bacterial suspension to plate to make the
310 final volume of 70 µl. The plate was then placed in Incucyte S3 for additional 5 days (Fig. 1).
311 The experiment layout was designed such as one well was used for each antibiotic treatment
312 and 33 wells were left for untreated controls on each plate and three replicated experiments
313 were performed. Planktonic and cording bacteria were always seeded on separate plates. We
314 performed also control experiment when H37Rv was growing as standing culture at 7H9

315 supplemented with ADC for 2-3 weeks, passaged into fresh medium and after 6 days of growth
 316 filtered through 0,5µm filter and seeded on 96-well plate in fresh medium with or without
 317 Tween-80.

318 **Fig. 1. Scheme of experimental layout**



319

320 **Table 2. Solvent used in preparation of antibiotics and concentrations used in assays.**

Antibiotic	Solvent	Dose response ranges (µg/ml)	Checkerboard assay* (µg/ml)
Rifampicin	DMSO	10 – 1x10 ⁻⁶	1
Isoniazid	H ₂ O	10 – 1x10 ⁻⁵	0.1
Linezolid	DMSO	10 – 0.01	1
Levofloxacin	DMSO	10 – 0.01	1
Ethambutol	DMSO	40 – 0.04	4
Clofazimine	DMSO	10 – 0.001	10
Moxifloxacin	H ₂ O	10 – 0.01	0.25
Pretomanid	DMSO	10 – 0.01	1

321 *subinhibitory concentrations

322 Analysis of live-cell imaging data

323 Fluorescent objects in both planktonic and cording model were identified with the help of
324 inbuilt IncuCyte S3 software enabling segmentation and background correction. Data on total
325 area (μm^2) of identified fluorescent objects were collected and exported from the Incucyte S3
326 into Excel and GraphPad (version 8.4.3.) for summarizing the results and statistical analysis.
327 Intra- and inter-assay variability was calculated as previously published (19). Variability of
328 total area measurements within each plate (intra-assay variability) was calculated based on
329 replicated (N=33) samples of untreated Rv after 7 days of growth. Variability of measurements
330 between plates (inter-assay variability) was based on total area measurements of untreated Rv at
331 three separate experiments (first well of 33 replicated was chosen for each experiment) at the
332 same incubation time. Both values were expressed as the coefficient of variation (CV%). Two-
333 way RM ANOVA with Sidaks's multiple comparison test was used to compare differences in
334 total area of fluorescent objects between untreated planktonic and cording bacteria. Total area
335 of objects after antibiotic treatment was normalized to the median of total area of all untreated
336 controls in each experiment (Additional files 3-6) and mean of three repetitive experiments
337 with standard deviation in error bars were than used in further analysis.

338

339 Analysis of frequency of object sizes

340 Data on frequency of sizes of fluorescent objects in untreated control wells in both models were
341 extracted from Incucyte software. Size intervals were chosen so they were logarithmically
342 distributed up to $10^4\mu\text{m}^2$. Since some measurements had no objects present, those points were
343 filtered out and median of replicated wells was used in further analysis. Difference between
344 untreated controls in planktonic and cording model was than analysed by multiple t-tests with

345 correction for multiple comparisons using Holm-Sidak method in GraphPad (version 8.4.3.) .
346 Data on frequency of object sizes in wells treated with antibiotics were after filtering out the
347 measurements without present objects analysed directly since there was only one well per
348 treatment in each experiment. Changes in distribution of objects sizes during the treatment of
349 bacteria with RIF and INH were analysed with multiple t-tests as mentioned for untreated
350 controls.

351

352 Analysis of dose response to antibiotics and MIC values

353 As recommended by GraphPad, IC50 values were calculated by fitting data into dose response
354 curves (inhibitor vs response) by nonlinear regression with three parameters and standard slope
355 for those antibiotics where only few concentrations were tested. Nonlinear regression with four
356 parameters and variable slope was used in case of RIF and INH, where 13 concentrations were
357 available. MIC defined as lowest concentration enough to effectively reduce the growth of
358 bacteria relatively to control was determined in GraphPad using modified Gompertz function
359 (30). The MIC was then transposed to nearest higher MIC value using the the log2-scale
360 according to ISO-standard.

361

362 Image acquisition, processing and statistical analysis of largest aggregates

363 To measure the growth of a single aggregate, images were analyzed through MATLAB image
364 processing with in-house scripts (scripts will be available upon request). Images were extracted
365 from large aggregate identified in well without antibiotics (Additional file 8: Movie S1). The

366 area of a particular aggregate was measured over time and changes of the area were calculated
367 using the formula,

368
$$\Delta A = A_{i+1} - A_i; \text{ and } \Delta t = t_{i+1} - t_i.$$

369 where ΔA is the change of area; Δt is the change of time, and i is the unit vector.

370

371 **Declarations**

372 Acknowledgements

373 We thank Lovisa Karlsson for her constructive suggestions and reviewing the manuscript.

374 Ethics approval and consent to participate

375 Not applicable

376 Consent for publication

377 Not applicable

378 Availability of data and materials

379 The datasets used and/or analysed during the current study are available from the corresponding
380 author on reasonable request.

381 Competing interests

382 The authors declare that they have no competing interests.

383 Funding

384 Olav Thon Foundation, Ekhaga foundation, The Swedish Heart Lung Foundation.

385 Authors' contributions

386 SK and BA (shared first authorship): Data acquisition, data analysis, writing and revision of the
387 manuscript, JD: Data analysis, writing and revision of the manuscript, TS: Supervision of the
388 study and revision of the manuscript. ML: Supervision of the study and revision of the
389 manuscript.

390

391

References

392

393 1. Adeniji AA, Knoll KE, Loots DT. Potential anti-TB investigational compounds and drugs
394 with repurposing potential in TB therapy: a conspectus. *Appl Microbiol Biotechnol.*
395 2020;104(13):5633-62.

396 2. Middlebrook G, Dubos RJ, Pierce C. Virulence and Morphological Characteristics of
397 Mammalian Tubercle Bacilli. *J Exp Med.* 1947;86(2):175-84.

398 3. Hall-Stoodley L, Brun OS, Polshyna G, Barker LP. *Mycobacterium marinum* biofilm
399 formation reveals cording morphology. *FEMS Microbiol Lett.* 2006;257(1):43-9.

400 4. Julian E, Roldan M, Sanchez-Chardi A, Astola O, Agusti G, Luquin M. Microscopic cords,
401 a virulence-related characteristic of *Mycobacterium tuberculosis*, are also present in nonpathogenic
402 mycobacteria. *J Bacteriol.* 2010;192(7):1751-60.

403 5. Kalsum S, Braian C, Koeken V, Raffetseder J, Lindroth M, van Crevel R, et al. The
404 Cording Phenotype of *Mycobacterium tuberculosis* Induces the Formation of Extracellular Traps in
405 Human Macrophages. *Front Cell Infect Microbiol.* 2017;7:278.

406 6. Arias L, Cardona P, Catala M, Campo-Perez V, Prats C, Vilaplana C, et al. Cording
407 *Mycobacterium tuberculosis* Bacilli Have a Key Role in the Progression towards Active Tuberculosis,
408 Which is Stopped by Previous Immune Response. *Microorganisms.* 2020;8(2).

409 7. Ufimtseva EG, Ereemeva NI, Petrunina EM, Umpeleva TV, Bayborodin SI, Vakhrusheva
410 DV, et al. *Mycobacterium tuberculosis* cording in alveolar macrophages of patients with pulmonary
411 tuberculosis is likely associated with increased mycobacterial virulence. *Tuberculosis (Edinb).*
412 2018;112:1-10.

413 8. Lerner TR, Queval CJ, Lai RP, Russell MR, Fearn A, Greenwood DJ, et al.
414 *Mycobacterium tuberculosis* cords within lymphatic endothelial cells to evade host immunity. *JCI*
415 *Insight.* 2020;5(10).

416 9. Manjunatha UH, Smith PW. Perspective: Challenges and opportunities in TB drug
417 discovery from phenotypic screening. *Bioorg Med Chem.* 2015;23(16):5087-97.

418 10. Grzelak EM, Choules MP, Gao W, Cai G, Wan B, Wang Y, et al. Strategies in anti-
419 *Mycobacterium tuberculosis* drug discovery based on phenotypic screening. *J Antibiot (Tokyo).*
420 2019;72(10):719-28.

421 11. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, et al. A
422 diarylquinoline drug active on the ATP synthase of *Mycobacterium tuberculosis*. *Science.*
423 2005;307(5707):223-7.

- 424 12. Andreu N, Fletcher T, Krishnan N, Wiles S, Robertson BD. Rapid measurement of
425 antituberculosis drug activity in vitro and in macrophages using bioluminescence. *J Antimicrob*
426 *Chemother.* 2012;67(2):404-14.
- 427 13. Katzir I, Cokol M, Aldridge BB, Alon U. Prediction of ultra-high-order antibiotic
428 combinations based on pairwise interactions. *PLoS Comput Biol.* 2019;15(1):e1006774.
- 429 14. Song OR, Deboosere N, Delorme V, Queval CJ, Deloison G, Werkmeister E, et al.
430 Phenotypic assays for *Mycobacterium tuberculosis* infection. *Cytometry A.* 2017;91(10):983-94.
- 431 15. Stanley SA, Barczak AK, Silvis MR, Luo SS, Sogi K, Vokes M, et al. Identification of host-
432 targeted small molecules that restrict intracellular *Mycobacterium tuberculosis* growth. *PLoS Pathog.*
433 2014;10(2):e1003946.
- 434 16. Christophe T, Jackson M, Jeon HK, Fenistein D, Contreras-Dominguez M, Kim J, et al.
435 High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular
436 antimycobacterial inhibitors. *PLoS Pathog.* 2009;5(10):e1000645.
- 437 17. Manning AJ, Ovechkina Y, McGillivray A, Flint L, Roberts DM, Parish T. A high content
438 microscopy assay to determine drug activity against intracellular *Mycobacterium tuberculosis*.
439 *Methods.* 2017;127:3-11.
- 440 18. Queval CJ, Song OR, Delorme V, Iantomasi R, Veyron-Churlet R, Deboosere N, et al. A
441 microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-
442 throughput/high-content screening. *J Vis Exp.* 2014(83):e51114.
- 443 19. Eklund D, Welin A, Schon T, Stendahl O, Huygen K, Lerm M. Validation of a medium-
444 throughput method for evaluation of intracellular growth of *Mycobacterium tuberculosis*. *Clin*
445 *Vaccine Immunol.* 2010;17(4):513-7.
- 446 20. Welin A, Raffetseder J, Eklund D, Stendahl O, Lerm M. Importance of phagosomal
447 functionality for growth restriction of *Mycobacterium tuberculosis* in primary human macrophages. *J*
448 *Innate Immun.* 2011;3(5):508-18.
- 449 21. Bernut A, Herrmann JL, Kissa K, Dubremetz JF, Gaillard JL, Lutfalla G, et al.
450 *Mycobacterium abscessus* cording prevents phagocytosis and promotes abscess formation. *Proc Natl*
451 *Acad Sci U S A.* 2014;111(10):E943-52.
- 452 22. Johansen MD, Kremer L. Large Extracellular Cord Formation in a Zebrafish Model of
453 *Mycobacterium kansasii* Infection. *J Infect Dis.* 2020;222(6):1046-50.
- 454 23. Lounis N, Vranckx L, Gevers T, Kaniga K, Andries K. In vitro culture conditions affecting
455 minimal inhibitory concentration of bedaquiline against *M. tuberculosis*. *Med Mal Infect.*
456 2016;46(4):220-5.
- 457 24. Leisching G, Pietersen RD, Wiid I, Baker B. Virulence, biochemistry, morphology and
458 host-interacting properties of detergent-free cultured mycobacteria: An update. *Tuberculosis*
459 (Edinb). 2016;100:53-60.
- 460 25. Leisching G, Pietersen RD, Mpongoshe V, van Heerden C, van Helden P, Wiid I, et al.
461 The Host Response to a Clinical MDR Mycobacterial Strain Cultured in a Detergent-Free Environment:
462 A Global Transcriptomics Approach. *PLoS One.* 2016;11(4):e0153079.
- 463 26. Cheng N, Porter MA, Frick LW, Nguyen Y, Hayden JD, Young EF, et al. Filtration
464 improves the performance of a high-throughput screen for anti-mycobacterial compounds. *PLoS*
465 *One.* 2014;9(5):e96348.
- 466 27. Svensson RJ, Niward K, Davies Forsman L, Bruchfeld J, Paues J, Eliasson E, et al.
467 Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis.
468 *Br J Clin Pharmacol.* 2019;85(10):2341-50.
- 469 28. Schon T, Jureen P, Giske CG, Chryssanthou E, Sturegard E, Werngren J, et al. Evaluation
470 of wild-type MIC distributions as a tool for determination of clinical breakpoints for *Mycobacterium*
471 *tuberculosis*. *J Antimicrob Chemother.* 2009;64(4):786-93.
- 472 29. Abuzeid N, Kalsum S, Koshy RJ, Larsson M, Glader M, Andersson H, et al.
473 Antimycobacterial activity of selected medicinal plants traditionally used in Sudan to treat infectious
474 diseases. *J Ethnopharmacol.* 2014;157:134-9.

475 30. Lambert RJ, Pearson J. Susceptibility testing: accurate and reproducible minimum
476 inhibitory concentration (MIC) and non-inhibitory concentration (NIC) values. J Appl Microbiol.
477 2000;88(5):784-90.

478

479 **Additional files**

480 **Additional file 1 Table S1.xlsx Frequency of aggregate sizes in untreated controls of**
481 **planktonic and cording bacteria.** Data represents median number of 33 replicated wells of
482 control untreated H37Rv.

483 **Additional file 2 Fig S1.tif Growth of planktonic and cording bacteria.** Growth was
484 measured as a difference in total area as absolute value A) or ratio over d0 B). Day 0 refers to
485 the time point when antibiotics were added after 2 days of pre-culture in the 96-well plate. Data
486 are represented as mean±SD (N=3) based on median value of 33 replicated wells in each
487 experiment.

488 **Additional file 3 Fig S2.tif Growth of planktonic bacteria exposed to rifampicin (RIF).**
489 Growth of aggregates at highest (10µg/ml) and lowest (1×10^{-6} µg/ml) concentration of
490 rifampicin based on differences in total growth as A), B) absolute values or C), D) normalized
491 to median of all wells with untreated controls (N=33) B). D0 refers to the time point when
492 antibiotics were added after 2 days of pre-culture in the 96-well plate. Data represents values
493 for each of three experiments separately.

494 **Additional file 4 Fig S3.tif Growth of cording bacteria exposed to rifampicin (RIF).**
495 Growth of aggregates at highest (10µg/ml) and lowest (1×10^{-6} µg/ml) concentration of
496 rifampicin based on differences in total growth as A), B) absolute values or C), D) normalized
497 to median of all wells with untreated controls (N=33) B). D0 refers to the time point when
498 antibiotics were added after 2 days of pre-culture in the 96-well plate. Data represents values
499 for each of three experiments separately.

500 **Additional file 5 Fig S4.tif Growth of planktonic bacteria exposed to isoniazid (INH).**

501 Growth of aggregates at highest (10 μ g/ml) and lowest (1x10⁻⁵ μ g/ml) concentration of isoniazid
502 based on differences in total growth as A), B) absolute values or C), D) normalized to median
503 of all wells with untreated controls (N=33) B). D0 refers to the time point when antibiotics were
504 added after 2 days of pre-culture in the 96-well plate. Data represents values for each of three
505 experiments separately.

506 **Additional file 6 Fig S5.tif Growth of cording bacteria exposed to isoniazid (INH).** Growth

507 of aggregates at highest (10 μ g/ml) and lowest (1x10⁻⁵ μ g/ml) concentration of isoniazid based
508 on differences in total growth as A), B) absolute values or C), D) normalized to median of all
509 wells with untreated controls (N=33) B). D0 refers to the time point when antibiotics were
510 added after 2 days of pre-culture in the 96-well plate. Data represents values for each of three
511 experiments separately.

512 **Additional file 7 Table S2.xlsx Intra- and inter-assay variability.** Variability between

513 growth measurements (total area as μ m²/image) within each plate and between plates presented
514 as coefficient of variation (%).

515 **Additional file 8 Movie S1.mp4 Growth of single aggregate.**

Figures





Figure 1

Scheme of experimental layout




Figure 2

Morphological appearance and size of aggregates in planktonic and cording models. H37Rv growing in DMEM as planktonic (A) and cording (B) bacteria are shown at different time points. H37Rv grown in broth with or without Tween-80 (Tween) as indicated (C). Frequency plots of the distribution of aggregate sizes at day -2 (D) and day 5 (E). Columns represent size intervals and are logarithmically distributed up to 104 μm^2 . NP (non-present) marks intervals where no objects were identified. Data are presented as mean \pm SD (N=3).




Figure 3

Frequency of aggregate sizes during bacterial growth and in response to rifampicin (RIF). A, C, E) Frequency plots summarizing data from planktonic phenotype and B, D, F) data from cording phenotype exposed to different concentrations of rifampicin after 3 and 5 days of incubation. G, H) Frequency plots of untreated controls for planktonic and cording phenotype respectively. Data are presented as mean \pm SD (N=3).




Figure 4

Frequency of aggregate sizes during bacterial growth and in response to isoniazid (INH). A, C, E) Frequency plots summarizing data from planktonic phenotype and B, D, F) data from cording phenotype exposed to different concentrations of isoniazid after 3 and 5 days of incubation. G, H) Frequency plots of untreated controls for planktonic and cording phenotype respectively. Data are presented as mean \pm SD (N=3).




Figure 5

Dose response to antibiotics. Total area of aggregates in wells treated with antibiotics normalized to median of untreated controls (N=33) were used to calculate IC_{50} values. Black dotted line represents IC_{50} value for planktonic and red dotted line IC_{50} value for cording phenotype as determined by nonlinear regression (inhibitor vs response) with 4 parameters (A, B) or 3 parameters (C-H). Data are presented as

mean of three experiments \pm SD. Dotted lines 198 cross x-axes at the point representing IC50 value for planktonic (black line) and cording (red line) models.




Figure 6

MIC values for rifampicin (RIF) and isoniazid (INH). Gompertz functions was used to calculate MIC values at day5 based on total area of aggregates normalized to median of untreated controls (N=33) of the A), C) planktonic and B), D) cording model.




Figure 7

Inhibition of Rv growth by combination of antibiotics. H37Rv were treated by combination of two antibiotics at sub-inhibitory concentrations (details in Table 2). Total area of aggregates in wells treated with antibiotics normalized to median of untreated controls (N=33) were used in analysis. Data are presented as mean \pm SD (N=3).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Additionalfile1TableS1.xlsx](#)
- [Additionalfile2FigS1.tif](#)
- [Additionalfile3FigS2.tif](#)
- [Additionalfile4FigS3.tif](#)
- [Additionalfile5FigS4.tif](#)
- [Additionalfile6FigS5.tif](#)
- [Additionalfile7TableS2.xlsx](#)
- [Additionalfile8MovieS1.mp4](#)